Clinical Dose Preparation of [177Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [177Lu]LuCl3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression

Menon, Sarath; Mitra, Arpit; Ak, Chakraborty; Tawate, Megha; Sahu, Sudeep; Rakshit, Sutapa; Gaikwad, Sujay; Dhotre, Geetanjali; Damle, Archana; Banerjee, Sharmila

doi:10.1089/cbr.2021.0230

Cited by 4 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…177 Lu has favorable characteristics for radioimmunotherapy. It emits both high-energy βray (Emax=761 KeV) and γ-rays (113 in 6.4% and 208 KeV in 13%) and decays with a half-life of 6.7 days [13], which is favorable for radioimmunotherapy.…”

Section: Introductionmentioning

confidence: 99%

177Lu Anti-angiogenic Radioimmunotherapy Targeting ATP synthase in Gastric Cancer Model

Park,

An,

Kim

et al. 2024

Preprint

View full text Add to dashboard Cite

This study investigated a novel radioimmunotherapy strategy for targeting tumor angiogenesis. We developed a radiopharmaceutical complex by labeling an anti-adenosine triphosphate syn-thase (ATPS) monoclonal antibody (mAb) with the radioisotope 177Lu using DOTA as a chelating agent. 177Lu-DOTA-ATPS mAb demonstrated high labeling efficiency (99.0%) and stability in se-rum. MKN-45 cancer cells exhibited the highest cellular uptake, which could be specifically blocked by unlabeled ATPS mAb. In mice, 177Lu-DOTA-ATPS mAb accumulated significantly in tumors, with a tumor uptake of 16.0 ± 1.5%ID/g on day 7. 177Lu-DOTA-ATPS mAb treatment sig-nificantly reduced the viability of MKN-45 cells in a dose-dependent manner. In a xenograft tumor model, this radioimmunotherapy strategy led to substantial tumor growth inhibition (82.8%). Furthermore, combining 177Lu-DOTA-ATPS mAb with sunitinib, an anti-angiogenic drug, en-hanced the therapeutic efficacy of sunitinib in the mouse model. Our study successfully developed 177Lu-DOTA-ATPS mAb, a radioimmunotherapy agent targeting tumor blood vessels. This ap-proach demonstrates significant promise for inhibiting tumor growth, both as a single therapy and in combination with other anti-cancer drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

177Lu Anti-angiogenic Radioimmunotherapy Targeting ATP synthase in Gastric Cancer Model

Park,

An,

Kim

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…177 Lu has favorable characteristics for radioimmunotherapy. It emits both high-energy β-ray (Emax = 761 KeV) and γ-rays (113 in 6.4% and 208 KeV in 13%) and decays with a half-life of 6.7 days [ 13 ], which is favorable for radioimmunotherapy.…”

Section: Introductionmentioning

confidence: 99%

177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model

Park,

An,

Kim

et al. 2024

Antibodies

View full text Add to dashboard Cite

This study investigated a novel radioimmunotherapy strategy for targeting tumor angiogenesis. We developed a radiopharmaceutical complex by labeling an anti-adenosine triphosphate synthase (ATPS) monoclonal antibody (mAb) with the radioisotope 177Lu using DOTA as a chelating agent. 177Lu-DOTA-ATPS mAb demonstrated high labeling efficiency (99.0%) and stability in serum. MKN-45 cancer cells exhibited the highest cellular uptake, which could be specifically blocked by unlabeled ATPS mAb. In mice, 177Lu-DOTA-ATPS mAb accumulated significantly in tumors, with a tumor uptake of 16.0 ± 1.5%ID/g on day 7. 177Lu-DOTA-ATPS mAb treatment significantly reduced the viability of MKN-45 cells in a dose-dependent manner. In a xenograft tumor model, this radioimmunotherapy strategy led to substantial tumor growth inhibition (82.8%). Furthermore, combining 177Lu-DOTA-ATPS mAb with sunitinib, an anti-angiogenic drug, enhanced the therapeutic efficacy of sunitinib in the mouse model. Our study successfully developed 177Lu-DOTA-ATPS mAb, a radioimmunotherapy agent targeting tumor blood vessels. This approach demonstrates significant promise for inhibiting tumor growth, both as a single therapy and in combination with other anti-cancer drugs.

show abstract

Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer

Pougoue Ketchemen,

Njotu,

Babeker

et al. 2024

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Clinical Dose Preparation of [¹⁷⁷Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [¹⁷⁷Lu]LuCl₃ for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression

Cited by 4 publications

References 50 publications

<sup>177</sup>Lu Anti-angiogenic Radioimmunotherapy Targeting ATP synthase in Gastric Cancer Model

<sup>177</sup>Lu Anti-angiogenic Radioimmunotherapy Targeting ATP synthase in Gastric Cancer Model

177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model

Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer

Contact Info

Product

Resources

About